All In Biotech

Drug Trial Radar · NCT07486817

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Aug 12, 2027

Study completion Aug 25, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study is to find out how well a medicine called zongertinib is tolerated in people with this type of lung cancer, when combined with chemotherapy, with or without pembrolizumab. Zongertinib works by targeting and blocking HER2, a protein involved in cancer cell growth. Participants are put into two groups randomly, which means by chance. One group gets zongertinib tablets combined with platinum-based chemotherapy. The other group gets the same treatment plus an additional medicine called pembrolizumab. Chemotherapy and pembrolizumab are given as an infusion into a vein. Participants take zongertinib by mouth once a day, while chemotherapy is given every 3 weeks for up to 3 months, followed by maintenance treatment for up to 2 years. Pembrolizumab is given every 3 weeks for up to 2 years. This study does not have a fixed duration. Participants can receive some of the study treatments for up to about 2 years and may continue to take zongertinib as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. Doctors regularly check the size of the tumor and whether it has spread. They also monitor participants' health and take note of any unwanted effects.

Conditions

  • Lung Cancer, Non-squamous, Non-small Cell

Interventions

  • ZongertinibDrug

    Zongertinib

  • CisplatinDrug

    Cisplatin

  • CarboplatinDrug

    Carboplatin

  • PemetrexedDrug

    Pemetrexed

  • PembrolizumabDrug

    Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of discontinuation and/or prolonged interruption (>7 days) of zongertinib due to treatment-related adverse events (AEs) in the first 2 cycles of treatmentTime frame: up to 6 weeks

Locations

20 sites in 8 countries. Site status is shown where the registry gives one.

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Not yet recruiting

  • Cabrini Health

    Malvern, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Shanghai Geriatric Medical Center

    Shanghai, China · Recruiting

  • CTR Leon Berard

    Lyon, France · Recruiting

  • INS Curie

    Paris, France · Recruiting

  • Universitätsklinikum Köln (AöR)

    Cologne, Germany · Recruiting

  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Kindai University Hospital

    Osaka, Sakai, Japan · Recruiting

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

  • The Royal Marsden Hospital, Chelsea

    London, United Kingdom · Recruiting

  • The Royal Marsden Hospital, Sutton

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.